Institutional Biosafety Committee
Meeting Minutes

The meeting was called to order on 6/24/2025 11:30 AM and a quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance
Voting Members Present:
Hwan Kim
Rachel Brownlee
Jorge Escobar
Nicholas Carpino
Jeronimo Cello
Christopher Kuhlow
Kimberly Bowe

Non-Voting Attendees, Staff and Guests Present:
Rebecca Dahl
Lu-Ann Kozlowski
Aimee Minton

Recording:
Erin Augello

ITEMS
1. **Meeting called to order at 11:30AM**

2. **Next Meeting Date and General Announcements**

The next meeting date is 7/22/2025. Dr. Carpino surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. **Review of Minutes from Last Meeting**

Review type: **Full Committee Review**

Action: **Approved**
Effective date: **6/24/2025**
Vote: **Total 7 for 7 Opposed 0 Abstained 0**

4. Continuing reviews requiring full IBC review
This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202500020 MAPK Modulation in RAW264.7

PI:	Donghui Zhu
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: National Institute on Aging, Grant Office ID: 157611 Funding Source ID: AG064798
Training:	PI and all laboratory staff have received appropriate training
Applicable Section of the NIH Guidelines that the Research Falls Under:	III-D
Containment Conditions:	Biological Containment Levels: • DH5a: BSL-1 • RAW264.7: BSL-2

Determination: Approved
Modifications (If Applicable):

i. In Section: Primary cells or cell lines
Item 1. In addition to replication-competent ecotropic murine leukemia virus (MLV), polytropic MLV have been detected in the cell culture supernatant of RAW 264.7 cells. Therefore, it is recommended to handle these cells at BSL-2. Please indicate BSL-2 within the table.

ii. In Section: Biohazards
Item 1. Please indicate BSL-2 as biocontainment level for RAW 264.7 cells.

iii. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. Section 3F does not apply. Please change to Section 3D.

iv. In Section: Risk Group and Containment Practices
Item 2. A risk assessment based on the BMBL guidelines indicates that BSL2 containment and practices are recommended when handling RAW264.7 cells, since polytropic MLVs can be shed from them and infect human cells.

v. In Section: Exposure Assessment and Protective Equipment
Item 1. Please describe potential consequences (e.g. insertional mutagenesis) due to potential exposure to polytropic MLV potentially shed by RAW264.7 cell lines.
Item 4.C Please note, certification of BSC is due to expire in less than a month. Please plan recertification and affirm in resubmitted protocol.

Effective Date: 6/25/2025
Project Expiration: 6/24/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

a. PROTO202500021 Metabolic Regulation

PI:	Qiuhua Yang
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: Stony Brook University, Grant Office ID: Funding Source ID:
Training:	PI and all laboratory staff have received appropriate training
Applicable Section of the NIH Guidelines that the Research Falls Under:	III-D
Containment Conditions:	Storage Containment Levels: Usage Containment Levels: • Biological Containment Levels: • Adenoviral virus: BSL-2 • Human Primary RPE cells: BSL-2 • Human primary retinal microvascular ECs: BSL-2 • Mouse Blood : BSL-1 • Human Primary Choroidal ECs: BSL-2 • ARP19: BSL-2 • iPSC-Derived RPE cells: BSL-2

Determination: Approved
Modifications (If Applicable):

i. In Section: Funding resources
Item 1. Please provide missing information, as requested.

ii. In Section: Biosafety Summary
Item 1. Please select the "Bacteria, Yeasts, Fungi, or Parasites" option from the drop down menu and provide the requested information on the new page.

iii. In Section: Biohazards
Item 1. List E. coli and provide requested information.

iv. In Section: Recombinant or Synthetic Nucleic Acid Usage
Item 1. Section III-E does not apply. Please remove. Only 3D applies.

v. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Item 12. Adenovirus vector is used in this protocol. Therefore, check YES and provide the requested information.

vi. In Section: Exposure Assessment and Protective Equipment
Item 4. Ensure certification of BSC and provide information in 4c. In addition, provide room number in 4a.

Effective Date: 6/25/2025
Project Expiration: 6/24/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

6. Report on Amendments Requiring Full IBC Review

a. AMEND202500051 mdig in breast cancer

PI:	Fei Chen
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	Training is NOT up to date. Chen, Thakur and Wang require ELS 003 and EOS 004.
Applicable Section of the NIH Guidelines that the Research Falls Under:	III-D
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):

i. Training is NOT up to date. Chen, Thakur and Wang require ELS 003 and EOS 004.
ii. In Section: Funding resources
Item 1. Provide requested information for American Cancer Society grant.
iii. In Section: Recombinant or Synthetic Nucleic Acid Work Description
Please remove the extensive additional procedural details (e.g., imaging schedules, animal procedures, tumor measurements, and general background) that fall outside the scope of the requested information re. rsNAMs.
iv. In Section: Risk Group and Containment Practices
Item 1. Please change to RG3, due to use of lentivirus.
v. In Section: Exposure Assessment and Protective Equipment
Item 1. Remove all description of lentivirus system. Describe potential deleterious consequences of exposure to replicating competent lentivirus. Also, please describe consequences of possible exposure to bloodborne pathogens due to use of human cell lines.
Item 4. Please provide correct date of annual BSC certification.

Effective Date: 6/10/2025
Project Expiration: 6/9/2026

Votes:

For:	7
Against:	0
Recused:	0
Absent:	1
Abstained:	0

b. Review of AMEND202500053 Triennial review

PI:	Bruce Demple
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	Training is NOT up to date. Demple and Xue require ELS 003 and EOS 004.
Applicable Section of the NIH Guidelines that the Research Falls Under:	III-D
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):

i. Training is NOT up to date. Demple and Xue require ELS 003 and EOS 004. Please complete training and notify IBC.
ii. In Section: Risk Group and Containment Practices
Item 2. According to the BMBL reference guide, BSL-2 + is not a valid safety level. Please change to BSL2.
iii In section: Exposure Assessment and Protective Equipment
Item 1. Please include cautionary information related to the potential for bloodborne pathogens with use of human cell lines.
Item 4. Annual BSC recertification required 6/20/2025 (date indicated for last certification is 6/20/2024).
iv. In Section: Waste Management
Item 3. Please confirm if the concentration of bleach used for decontamination will be 1% or 10%.

Effective Date: 6/28/2025
Project Expiration: 6/27/2026

Votes:

For:	7
Against:	0
Recused:	0

Absent:	1
Abstained:	0

7. Review Of Incidents
None

8. Review of Other Agenda Items
None

9. Inspection Results
All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion Items/Readings (major and minor points of order)
None

11. Meeting Adjourned at 12:02PM